Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s Disease

Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s Disease   NEW YORK – January 11, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s…

Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference

Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference   NEW YORK – January 6, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central…